Shares of Mural Oncology plc (NASDAQ:MURA - Get Free Report) traded up 8.8% on Thursday . The stock traded as high as $4.44 and last traded at $4.43. 287,501 shares were traded during mid-day trading, an increase of 41% from the average session volume of 204,238 shares. The stock had previously closed at $4.07.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of Mural Oncology in a research note on Monday, November 11th.
Check Out Our Latest Stock Report on MURA
Mural Oncology Trading Down 4.3 %
The company has a market capitalization of $72.85 million, a price-to-earnings ratio of -0.47 and a beta of 3.90. The stock has a 50-day simple moving average of $3.69 and a 200-day simple moving average of $3.50.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the stock. Commerce Bank acquired a new position in shares of Mural Oncology in the 3rd quarter worth approximately $39,000. FMR LLC boosted its holdings in Mural Oncology by 124.7% in the third quarter. FMR LLC now owns 20,580 shares of the company's stock worth $64,000 after purchasing an additional 11,423 shares during the period. Dimensional Fund Advisors LP bought a new stake in Mural Oncology during the second quarter valued at $71,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Mural Oncology during the second quarter worth $98,000. Finally, Raymond James Financial Inc. bought a new position in shares of Mural Oncology in the 4th quarter worth about $181,000. 80.21% of the stock is currently owned by institutional investors.
Mural Oncology Company Profile
(
Get Free Report)
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Featured Articles
Before you consider Mural Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mural Oncology wasn't on the list.
While Mural Oncology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
